Burning Rock Biotech Limited (BNR) Fair Value 2026

BNR · Diagnostics & Research ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.5 /10

32 fundamental signals · 1 models active

Value Trap Risk

LOW (31/100)

Quick Summary — As of 2026-08-28, Burning Rock Biotech Limited (BNR) trades at $10.19. QOC: 6.5/10. Value Trap Risk: 31/100 (LOW). 1/13 models active.

Key Facts

Ticker
BNR
Price
$10.19
Quality Score
6.5/10
Value Trap Risk
31/100
Models Active
1/13
Last Updated
Strength: Dynamic NAV suggests +7.2% upside with 47% confidence
Risk: Limited model coverage (1/13) may reduce confidence

What Fair Value Does Each Model Give BNR?

1 Intrinsic Value Models vs. Current Price ($10.19)

Core Models (Unlocked)
Model Fair Value Upside
Asset-Based · Medium Conviction
 $10.92 +7.2%

All Models Active

All 1 models are displayed above.

What Is Burning Rock Biotech Limited (BNR) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Burning Rock Biotech Limited's intrinsic value is estimated at a median fair value of $10.92. At a current market price of $10.19, 1 of 1 active valuation models identify upside potential, projecting a median implied return of +7.2%.

What Do the Models Say About BNR?

1 of 13 models are currently active for BNR. All 1 active models suggest the stock trades below fair value. See which stocks rank higher →

How Does BNR Rank in Diagnostics & Research?

Among 52 Diagnostics & Research stocks, BNR ranks #31 by Quality of Company score. CirclFi's QOC score of 6.5/10 evaluates 32 fundamental signals. A score of 6.5 indicates above-average quality.

Burning Rock Biotech Limited's positioning within the Diagnostics & Research segment means that revenue per drug plays an outsized role in fundamental analysis. The sector's unique characteristics — including therapeutic area leadership — shape both the opportunity set and risk profile.

Is BNR a Value Trap?

CirclFi's Value Trap algorithm assigns BNR a score of 31/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for Burning Rock Biotech Limited. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, Burning Rock Biotech Limited scores 6.5 out of 10 on our 32-signal quality assessment, a solid rating that maintains reasonable quality metrics with some areas for improvement. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every BNR valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across BNR's 1 active models, average confidence is 47%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Burning Rock Biotech Limited Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Diagnostics & Research Stocks Should You Also Analyze?

11 related Diagnostics & Research stocks with 13-model coverage

MYGNMyriad Genetics, Inc.QOC 6.6WGSGeneDx Holdings Corp.QOC 6.4NEONeoGenomics, Inc.QOC 6.6PSNLPersonalis, Inc.QOC 6.4RDNTRadNet, Inc.QOC 6.7AWHLAspira Women's Health Inc.QOC 6.4FRNMFreenome, Inc.QOC 4.8ILMNIllumina, Inc.QOC 8.8RVTYRevvity, Inc.QOC 7.4IDXXIDEXX Laboratories, Inc.QOC 9.5MEDPMedpace Holdings, Inc.QOC 9.3

Read investment analysis: MYGN · WGS · NEO · PSNL · RDNT · AWHL · FRNM · ILMN · RVTY · IDXX · MEDP

Which Other Stocks Have a Similar Quality Score to BNR?

7 companies across all industries closest to BNR’s Quality of Company score of 6.5/10.

KVHIKVH Industries, Inc.QOC 6.5MNTKMontauk Renewables, Inc.QOC 6.5VRDNViridian Therapeutics, Inc.QOC 6.5TNDMTandem Diabetes Care, Inc.QOC 6.5KRMDKORU Medical Systems, Inc.QOC 6.5VNCEVince Holding Corp.QOC 6.5NVDANVIDIA CorporationQOC 10.0

Read investment analysis: KVHI · MNTK · VRDN · TNDM · KRMD · VNCE · NVDA

What Else Do Investors Ask About Burning Rock Biotech Limited’s Valuation?

What is Burning Rock Biotech Limited's intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Burning Rock Biotech Limited (BNR). The Quality of Company score is 6.5/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is BNR overvalued or undervalued right now?

At $10.19, 1 of 1 active models suggest BNR may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Burning Rock Biotech Limited's business model in Diagnostics & Research.

What does a Quality of Company score of 6.5 mean for BNR?

Burning Rock Biotech Limited's QOC of 6.5/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on BNR?

CirclFi analyzes BNR with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is BNR a value trap in 2026?

Burning Rock Biotech Limited's Value Trap score is 31/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Burning Rock Biotech Limited (BNR) a Quality of Company score of 6.5/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/BNR/ · Methodology
Primary sources for this BNR valuation
  • Financial statements: Burning Rock Biotech Limited 10-K and 10-Q filings on SEC EDGAR (CIK 0001792267) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for BNR as of ; valuations recomputed .